Experience and Expertise
Jesse is the Global Head of Marketing for Sirtex and a member of the Senior Leadership Team. Under his direction, there is a continued focus on the global development and growth of Sirtex’s targeted interventional oncology markets, commercial capabilities and relationships with external partners.
With more than 15 years in the medical device industry, Jesse is well versed in the interventional radiology and oncology space. Prior to joining Sirtex in 2020, he served as Vice President of Corporate Product Marketing for Merit Medial Systems, Inc., where he led a team responsible for product development, strategic distribution partnerships and acquisition-related activities. Jesse also worked as Senior Product Manager at Becton Dickinson (formerly C.R. Bard-Davol) and managed the company’s largest soft tissue repair portfolio. Before that, he had global marketing responsibilities for Medtronic’s vascular therapy deep-vein-thrombosis-prevention portfolio.
Jesse holds a Master of Business Administration with an emphasis in marketing and a bachelor’s degree in business management from the University of Phoenix.
Kevin R. Smith
CEO
Paul Andreassi
Executive Vice President of Global Quality Assurance
Jesse Hansen
Global Head of Marketing
Francis Jannot
Executive Vice President of International Sales
Cathleen Lowndes
Chief Human Resources Officer
Amy Pan
Chief Financial Officer
Suki Shergill
Executive Vice President, Global Pricing & Market Access
Kevin P. Smith
General Counsel & Executive Vice President, Business Development
Grant Spindler
Global Head of Operations
MaryLou Stroumbos
Executive Vice President, Regulatory Affairs
Mark Turco
Global Chief Medical Officer & Executive Vice President of Research & Development
You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.
Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.
Click 'Continue' to proceed to the third-party Web site.
You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.
Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes
no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.
The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region.
Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.
Click 'Continue' to proceed to the other Sirtex region Web site.
Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and
unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.
Click here to view our Technical Bulletin.